Literature DB >> 17609921

[PDE5 inhibitors in treatment of benign prostatic syndrome].

P Sandner1, H Tinel, B Stelte-Ludwig, J Huetter, D Neuser, E Bischoff, E Ulbrich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17609921     DOI： 10.1007/s00120-007-1478-3

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  12 in total

Review 1.  Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life.

Authors:  D J Carbone; S Hodges
Journal:  Int J Impot Res       Date:  2003-08       Impact factor: 2.896

Review 2.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

3.  Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate.

Authors:  S Uckert; A Küthe; U Jonas; C G Stief
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

4.  Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Jed C Kaminetsky; Stephen M Auerbach; Barton Wachs; Jay M Young; Anne Esler; Gregory D Sides; Bela S Denes
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

Review 5.  Regulation of cyclic nucleotides in the urinary tract.

Authors:  Marcia A Wheeler; Rajasekhara R Ayyagari; George L Wheeler; Robert M Weiss
Journal:  J Smooth Muscle Res       Date:  2005-02

6.  Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.

Authors:  Kevin T McVary; William Monnig; Joseph L Camps; Jay M Young; Li-Jung Tseng; Gene van den Ende
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

7.  Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate.

Authors:  Stefan Uckert; Matthias Oelke; Christian G Stief; K-E Andersson; Udo Jonas; Petter Hedlund
Journal:  Eur Urol       Date:  2006-01-18       Impact factor: 20.096

8.  Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate.

Authors:  P Drescher; R E Eckert; P O Madsen
Journal:  Prostate       Date:  1994-08       Impact factor: 4.104

9.  Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia.

Authors:  T N Chirikos; E Sanford
Journal:  J Urol       Date:  1996-04       Impact factor: 7.450

10.  A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men.

Authors:  S J Jacobsen; H A Guess; L Panser; C J Girman; C G Chute; J E Oesterling; M M Lieber
Journal:  Arch Fam Med       Date:  1993-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.